Skip to Content

XTENT to Present CUSTOM I and CUSTOM II Trial Data at TCT 2007

Company Also to Host Drug-Eluting Stent Symposium and Analyst Webcast

MENLO PARK, Calif., October 16, 2007 /PRNewswire-FirstCall/ -- XTENT, Inc. today announced that 2-year data from the CUSTOM I trial and 1-year data from the CUSTOM II trial of the company's investigational Custom NX(R) drug-eluting stent (DES) system will be presented at the Cardiovascular Research Foundation's (CRF) nineteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C., which is taking place October 20 to 25.

In addition, the company will conduct a number of activities during the meeting including an analyst webcast and teleconference to review the CUSTOM I and CUSTOM II clinical data, an evening drug-eluting stent symposium, and an exhibition at booth 6097 on Level 2 of the Washington Convention Center.

    Schedule of Events

    Sunday, October 21

    Event: The Drug-Eluting Stent Summit: The XTENT CUSTOM Biolimus-Eluting

    Modular Stent Program (Focus on Multivessel and Diffuse Disease)

    Pieter Stella, M.D., Director of Cardiology, University Medical Center,

    Utrecht, Netherlands, will present a historical overview and current

    perspective on the treatment of multivessel coronary disease and the

    treatment of long lesions. An overview of the Custom NX(R) DES System with

    respect to the treatment of multivessel and diffuse disease will be

    discussed, along with the one-year follow-up results of the CUSTOM II


    Time/Location: 3:16-3:26 p.m. EDT; Ballroom C, 3rd Floor, Washington

    Convention Center

    Event: Evening Symposium -- Delivering Safety to Today's Patients

    Professor Eberhard Grube, M.D., Chief of Cardiology at the HELIOS Heart

    Center in Siebgurg, Germany and principal investigator of the CUSTOM I and

    II clinical trials, will review the results to date from Biolimus A9(R)

    DES clinical trials and registries.  Professor Grube will present two-year

    results from the CUSTOM I clinical trial and one-year results from the

    CUSTOM II clinical trial.

    Bernard de Bruyne, M.D. Ph.D, Cardiovascular Center, OLV Hospital in

    Aalst, Belgium, will provide an overview of the Custom NX technology in a

    presentation titled "XTENT Custom NX DES Systems: A Novel Approach to the

    Percutaneous Treatment of Coronary Artery Disease (CAD)."

    Time/Location: 8:00-10:00 p.m. EDT; Renaissance Washington, D.C. Hotel,

    Grand Ballroom, 999 Ninth Street NW

    Monday, October 22

    Event: Analyst Webcast and Teleconference on CUSTOM I and CUSTOM II Data

    XTENT will host a webcast and teleconference call to review the CUSTOM I

    and CUSTOM II data presented on Sunday. The teleconference and slide

    presentation can be accessed via the investor relations section of the

    company's website at or by calling

    888-663-2258 (from the U.S.), 913-312-1277 (international). Please dial in

    or access the website five to ten minutes prior to the beginning of the

    call. The webcast will be archived on the website for a minimum of three

    months, and can be accessed at the investor relations portion of the

    company's website

    Time/Location: 7:00 a.m. EDT


XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device. Note: XTENT Custom NX DES Systems have not been approved for sale by any regulatory authority.

CONTACT: investors, Tim Kahlenberg, Chief Financial Officer of XTENT,Inc., +1-650-475-9400, ; or media relations, AimeeCorso, +1-310-780-2661, , for XTENT, Inc.

Ticker Symbol: (NASDAQ-NMS:XTNT)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: October 2007